BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

...approve shipment of the doses. “It is evident this specific opportunity is over and the NRC...
BioCentury | May 13, 2020
Product Development

Gilead secures global access to remdesivir via generic manufacturing deals

...Separately Tuesday, CanSino Biologics Inc. (HKEX:6185) partnered with the National Research Council of Canada (NRC...
...collaboration builds on a 2013 licensing deal for a HEK cell line designed at the NRC...
...also build out its vaccine bioprocessing capabilities and has allotted $44 million to upgrade the NRC’s...
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Jul 18, 2018
Emerging Company Profile

Ministring theory in practice

...Nanosystems Inc. Number of employees: 3 Funds raised: C$1.1 million ($837,000) Investors: Wing VCs, MITACS, NRC...
BioCentury | Dec 19, 2017
Politics & Policy

Federal funding ban lifted for pathogen research

...Science Advisory Board for Biosecurity (NSABB) and the National Research Council of the National Academies (NRC...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...angel investors, and received grants from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP...
BioCentury | Jun 7, 2017
Distillery Techniques


TECHNOLOGY: Tissue markers Three multigene signatures could predict survival in breast cancer patients. In 2,333 patients, genetic profiling of tumor samples identified associations between expression patterns in a panel of 12 genes -- including adenosine...
BioCentury | Mar 3, 2017
Company News

National Research Council Canada, Helix deal

...cell lung cancer (NSCLC). The partners did not respond to inquiries. National Research Council Canada (NRC...
BioCentury | Apr 21, 2016
Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 3 (NCOA3; SRC3; AIB1)

Cancer INDICATION: Breast cancer; cancer In vitro testing, cell culture and mouse studies identified a small molecule inhibitor of NCOA3 that could help treat triple-negative breast cancer (TNBC). Screening of a small molecule library, in...
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 1 (NCOA1; SRC1); NCOA2 (SRC2); NCOA3 (SRC3; AIB1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest co-stimulating NCOA1 , NCOA2 and NCOA3 could help treat cancer. In multiple human cancer cell lines, a small molecule research compound that stimulated NCOA1, NCOA2 and NCOA3...
Items per page:
1 - 10 of 44